Alzheimer s Disease
Conditions
Keywords
Alzheimer Disease, Virtual Reality, Kinect xbox 360
Brief summary
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).
Detailed description
In the line with global epidemiology trend, the prevalence of AD is also rising at the regional level. In the United States, approximately 6.2 million individual aged 65 and older recently living with AD, and this figured is expected to reach 13.8 million by 2060 (Doher et al., 2023). Similarly, in Europe, the prevalence of AD is estimated at 5.05%, with a notably higher incidence in women (7.13%) as compared to men (3.31%) (Niu et al., 2017). Moreover, Asia alone has a higher prevalence of dementia patients than both America and Europe. A study conducted in tertiary care centers in Karachi showed that 63% of dementia patients had AD (Siddiqui et al., 2018).
Interventions
Experimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks.
The intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025). The patients will take 1-2 minutes rest after 5 minutes of activity. Rest periods of 1-2 minutes after every 5 minutes of activity.
Sponsors
Study design
Masking description
All participants will be blinded regarding treatment. A total of 38 patients will be recruited and assigned into two groups. Group A will receive Kinect Xbox game therapy exercises and Group B will receive Conventional Circuit Exercises
Intervention model description
Experimental Group Kinect game-based Rehabilitation: Device Kinect XBOX 360. Kinect game will be given 30 sessions, and intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks, The patients will take 1-2 minutes rest after 5 minutes of activity. Placebo Comparator: Control Group: Conventional Rehabilitation: Conventional exercises will be given 30 sessions, and intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks, The patients will take 1-2 minutes rest after 5 minutes of activity.
Eligibility
Inclusion criteria
* Alzheimer's disease of age between 50-85 years. * Diagnosed AD stage Mild to Moderate.
Exclusion criteria
* Undiagnosed AD patients. * Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognition | Baseline | Cognitive function will be assessed through among mild to moderate AD patients where low values indicate decrease in cognitive ability. |
| Motor Function | Baseline | Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate poorer functional mobility |
| Quality of Life (QOL) | Baseline | Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life. |
| Quality Of Life (QOL) | After 6 weeks of Intervention | Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life. |
Countries
Pakistan
Contacts
Ziauddin University, Karachi, Sindh, Pakistan